BRISTOL-MYERS SQUIBB CO (BRM.DE) Fundamental Analysis & Valuation

FRA:BRM • US1101221083

Current stock price

50.27 EUR
-0.03 (-0.06%)
Last:

This BRM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BRM.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BRM was profitable.
  • In the past year BRM had a positive cash flow from operations.
  • BRM had positive earnings in 4 of the past 5 years.
  • In the past 5 years BRM always reported a positive cash flow from operatings.
BRM.DE Yearly Net Income VS EBIT VS OCF VS FCFBRM.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • BRM has a Return On Assets (7.83%) which is in line with its industry peers.
  • BRM has a better Return On Equity (38.19%) than 92.16% of its industry peers.
  • BRM has a better Return On Invested Capital (19.52%) than 84.31% of its industry peers.
  • BRM had an Average Return On Invested Capital over the past 3 years of 14.47%. This is in line with the industry average of 13.61%.
  • The 3 year average ROIC (14.47%) for BRM is below the current ROIC(19.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROIC 19.52%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
BRM.DE Yearly ROA, ROE, ROICBRM.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • The Profit Margin of BRM (14.64%) is better than 62.75% of its industry peers.
  • In the last couple of years the Profit Margin of BRM has grown nicely.
  • BRM's Operating Margin of 35.82% is amongst the best of the industry. BRM outperforms 90.20% of its industry peers.
  • In the last couple of years the Operating Margin of BRM has grown nicely.
  • BRM's Gross Margin of 72.63% is in line compared to the rest of the industry. BRM outperforms 58.82% of its industry peers.
  • BRM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
BRM.DE Yearly Profit, Operating, Gross MarginsBRM.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

5

2. BRM.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
  • Compared to 1 year ago, BRM has more shares outstanding
  • The number of shares outstanding for BRM has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BRM has an improved debt to assets ratio.
BRM.DE Yearly Shares OutstandingBRM.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B
BRM.DE Yearly Total Debt VS Total AssetsBRM.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • BRM has an Altman-Z score of 2.52. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BRM has a Altman-Z score (2.52) which is in line with its industry peers.
  • BRM has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BRM would need 3.51 years to pay back of all of its debts.
  • BRM's Debt to FCF ratio of 3.51 is fine compared to the rest of the industry. BRM outperforms 62.75% of its industry peers.
  • A Debt/Equity ratio of 2.33 is on the high side and indicates that BRM has dependencies on debt financing.
  • BRM has a Debt to Equity ratio of 2.33. This is amonst the worse of the industry: BRM underperforms 80.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Altman-Z 2.52
ROIC/WACC2.22
WACC8.8%
BRM.DE Yearly LT Debt VS Equity VS FCFBRM.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B 50B

2.3 Liquidity

  • BRM has a Current Ratio of 1.26. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
  • BRM has a Current ratio (1.26) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.14 indicates that BRM should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.14, BRM is doing good in the industry, outperforming 68.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.14
BRM.DE Yearly Current Assets VS Current LiabilitesBRM.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2

3. BRM.DE Growth Analysis

3.1 Past

  • BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
  • BRM shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
  • BRM shows a decrease in Revenue. In the last year, the revenue decreased by -0.22%.
  • BRM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.15% on average over the next years.
  • Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.54% on average per year.
EPS Next Y2.96%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
EPS Next 5Y-4.15%
Revenue Next Year-1.82%
Revenue Next 2Y-2.01%
Revenue Next 3Y-5.44%
Revenue Next 5Y-5.54%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BRM.DE Yearly Revenue VS EstimatesBRM.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BRM.DE Yearly EPS VS EstimatesBRM.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

7

4. BRM.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.59, the valuation of BRM can be described as reasonable.
  • BRM's Price/Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 90.20% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.50. BRM is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 9.32, which indicates a very decent valuation of BRM.
  • 90.20% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
  • BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.62.
Industry RankSector Rank
PE 9.59
Fwd PE 9.32
BRM.DE Price Earnings VS Forward Price EarningsBRM.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 90.20% of the companies are valued more expensively.
  • BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 88.24% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.38
EV/EBITDA 7.25
BRM.DE Per share dataBRM.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BRM does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of BRM may justify a higher PE ratio.
  • A cheap valuation may be justified as BRM's earnings are expected to decrease with -4.23% in the coming years.
PEG (NY)3.25
PEG (5Y)N/A
EPS Next 2Y0.32%
EPS Next 3Y-4.23%

7

5. BRM.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.27%, BRM is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.89, BRM pays a better dividend. On top of this BRM pays more dividend than 82.35% of the companies listed in the same industry.
  • BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 4.27%

5.2 History

  • On average, the dividend of BRM grows each year by 6.51%, which is quite nice.
Dividend Growth(5Y)6.51%
Div Incr Years4
Div Non Decr Years4
BRM.DE Yearly Dividends per shareBRM.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 71.52% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
  • The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
BRM.DE Yearly Income VS Free CF VS DividendBRM.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BRM.DE Dividend Payout.BRM.DE Dividend Payout, showing the Payout Ratio.BRM.DE Dividend Payout.PayoutRetained Earnings

BRM.DE Fundamentals: All Metrics, Ratios and Statistics

BRISTOL-MYERS SQUIBB CO

FRA:BRM (4/23/2026, 3:30:04 PM)

50.27

-0.03 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners83.83%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap102.64B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.56
Price Target53.87 (7.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.27%
Yearly Dividend2.13
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)2.8%
PT rev (3m)10.5%
EPS NQ rev (1m)-1.66%
EPS NQ rev (3m)-0.94%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)4.46%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)3.34%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)6.73%
Valuation
Industry RankSector Rank
PE 9.59
Fwd PE 9.32
P/S 2.5
P/FCF 9.38
P/OCF 8.51
P/B 6.52
P/tB N/A
EV/EBITDA 7.25
EPS(TTM)5.24
EY10.42%
EPS(NY)5.4
Fwd EY10.74%
FCF(TTM)5.36
FCFY10.67%
OCF(TTM)5.91
OCFY11.75%
SpS20.12
BVpS7.71
TBVpS-9.34
PEG (NY)3.25
PEG (5Y)N/A
Graham Number30.1523 (-40.02%)
Profitability
Industry RankSector Rank
ROA 7.83%
ROE 38.19%
ROCE 25.91%
ROIC 19.52%
ROICexc 23.22%
ROICexgc 84.94%
OM 35.82%
PM (TTM) 14.64%
GM 72.63%
FCFM 26.65%
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.33
Debt/FCF 3.51
Debt/EBITDA 2.03
Cap/Depr 32.69%
Cap/Sales 2.72%
Interest Coverage 8.22
Cash Conversion 66.54%
Profit Quality 182.1%
Current Ratio 1.26
Quick Ratio 1.14
Altman-Z 2.52
F-Score7
WACC8.8%
ROIC/WACC2.22
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y2.96%
EPS Next 2Y0.32%
EPS Next 3Y-4.23%
EPS Next 5Y-4.15%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.82%
Revenue Next 2Y-2.01%
Revenue Next 3Y-5.44%
Revenue Next 5Y-5.54%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year23.35%
EBIT Next 3Y2.42%
EBIT Next 5Y-1.47%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%

BRISTOL-MYERS SQUIBB CO / BRM.DE Fundamental Analysis FAQ

What is the fundamental rating for BRM stock?

ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE.


What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.


Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for BRM stock?

The Price/Earnings (PE) ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 9.59 and the Price/Book (PB) ratio is 6.52.


Can you provide the financial health for BRM stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.